Alert: New Earnings Report (11/6/23)-Axsome Therapeutics Inc (NASDAQ: AXSM).


Axsome Therapeutics Inc (NASDAQ: AXSM) has reported a loss for its third fiscal quarter (ending September 30) of $-1.32 versus a loss $-1.07 for the same period a year ago. This performance was $-0.13 short of the consensus estimate of $-1.19. For the latest four quarters through September 30, E.P.S. were $-4.55 compared to $-4.07 a year ago.


Recent Price Action

On 11/6/23, Axsome Therapeutics Inc (NASDAQ: AXSM) stock suffered a large decline of -4.2%, closing at $62.42. The stock has been strong relative to the market over the last nine months and has risen 0.5% during the last week.

Current PriceTarget Research Rating

Reflecting future returns on capital that are forecasted to be in line with the cost of capital, AXSM is expected to continue to be Value Creation neutral.

Axsome Therapeutics has a current Value Trend Rating of D (Negative). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. Axsome Therapeutics has a very low Appreciation Score of 1 but a good Power Rating of 70, producing the Negative Value Trend Rating.

Rating Review

In light of this new information we are reviewing our current Overall Rating of D. This review will be completed in the next several days.

Be the first to comment

Leave a Reply

Your email address will not be published.